# Clinical Trials Data KRAS - Document 45

# The Roles of Neutrophil Elastase in Lung Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01360931

"eligibilityCriteria": "Inclusion Criteria:\n\n\* All subjects undergoing clinical diagnostic or therapeutic procedures, including:\n\n 1. Fibreoptic bronchoscopy or pleuroscopy\n 2. Diagnostic or Therapeutic pleurocentesis AND who are mentally fit to give informed consent for donation of clinical specimens\n\nExclusion Criteria:\n\n\* Patients who cannot give written informed consent or refuse to give such consent for participation in this study",  
 "healthyVolunteers": true,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Subjects undergoing diagnostic bronchoscopy",

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't mention anything about KRAS gene mutation status as an inclusion or exclusion criterion. Therefore, having a KRAS mutation would \*not\* automatically exclude a patient from this trial. As long as the patient meets the other inclusion criteria (undergoing one of the specified procedures and able to give informed consent) and doesn't meet any of the exclusion criteria (unable/unwilling to give informed consent), they would likely be eligible regardless of their KRAS status.